Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq:LXRX) reported second quarter 2026 revenues of $0.7 million, down from $28.9 million a year earlier, reflecting the absence of prior-period Novo Nordisk licensing revenue. The company posted a net loss of $31.8 million, or $0.07 per share, versus net income of $3.3 million, or $0.01 per share, in 2025.
R&D expenses rose to $17.4 million and SG&A to $9.8 million. Cash and investments increased to $190.6 million, aided by $96.2 million of February equity proceeds and a new $100 million Hercules Capital loan facility, of which $55 million was drawn to refinance prior debt.
Lexicon completed enrollment of the >500-patient Phase 3 SONATA-HCM study of sotagliflozin, with topline data expected in Q1 2027, and plans an NDA resubmission for ZYNQUISTA in type 1 diabetes in Q4 2026. Novo Nordisk’s Phase 1 obesity program for LX9851 is ongoing, with Lexicon eligible for up to $1 billion in milestones plus royalties.
Positive
- SONATA-HCM Phase 3 enrollment completed with >500 patients; topline data expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes targeted for Q4 2026, supported by ongoing STENO1 safety data
- Cash and investments increased to $190.6 million at June 30, 2026, from $125.2 million at year-end 2025
- Novo Nordisk LX9851 deal: $45 million upfront plus two $10 million clinical milestones received; eligibility for up to $1 billion in further milestones and tiered royalties
- $100 million Hercules Capital loan facility secured; initial $55 million tranche funded and used to repay prior Oxford Finance loan
- Viatris ex-U.S. approvals and filings for sotagliflozin in heart failure, including approvals in UAE and Bahrain and submissions in multiple additional markets
Negative
- Total revenues declined to $0.7 million in Q2 2026 from $28.9 million in Q2 2025, due to the absence of prior-period Novo Nordisk licensing revenue
- Net result swung from $3.3 million income in Q2 2025 to a $31.8 million loss in Q2 2026
- R&D expenses increased to $17.4 million from $15.7 million year over year, driven by SONATA-HCM trial costs
- SG&A expenses rose to $9.8 million from $9.4 million, reflecting higher professional and consulting costs
- Loss on early extinguishment of debt of $4.3 million recorded in connection with refinancing
- Share count increased to 437.7 million basic average shares in Q2 2026 from 363.3 million a year earlier, following $96.2 million of equity issuance
News Explained
The
Market reaction after 2Q26 earnings report: LXRX -18.37%
Following this news, LXRX has declined 18.37%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.9% during the session. Our momentum scanner has triggered 15 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $2.00.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 earnings report | Positive | +5.0% | Revenue milestone, liquidity update, loan facility, and pipeline progress accompanied quarterly results. |
| Mar 05 | Q4 earnings report | Positive | +0.6% | Pipeline milestones and new financing strengthened the quarterly business update. |
| Nov 06 | Q3 earnings report | Positive | +3.6% | Licensing revenue, improved loss, and clinical development progress drove the update. |
| Aug 06 | Q2 earnings report | Positive | +9.5% | Higher revenue, improved profitability, and pipeline progress defined the quarterly announcement. |
| May 13 | Q1 earnings report | Positive | -15.6% | Novo Nordisk licensing, clinical progress, and improved loss accompanied the quarterly results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with four positive 24-hour moves and one negative move; the recorded tag-specific average was 0.64%.
Key Terms
nda regulatory
sglt1 medical
acsl5 medical
aak1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027
NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion
Phase 1 clinical development of LX9851 ongoing by Novo Nordisk
Conference call and webcast at 8:30 am ET
THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments.
“Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “Among all the accomplishments, I’m particularly pleased that we have completed enrollment of our SONATA-HCM study on time, reflecting strong clinical interest for a novel class of medicine to treat HCM. Overall, I could not be more confident in how these opportunities are poised to shape the company over the coming months.”
“We remain very focused on disciplined, targeted capital allocation as we continue to advance our clinical programs,” said Scott Coiante, Lexicon’s chief financial officer. “With early commercial planning now underway for our late-state pipeline, we are committed to maximizing the value of these opportunities to create long-term shareholder value.”
Second Quarter 2026 Business and Pipeline Highlights
Cardiometabolic
Sotagliflozin
Sotagliflozin is a unique oral inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA®.
Hypertrophic Cardiomyopathy (HCM)
- Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study, substantially exceeding its enrollment target of 500 patients across both non-obstructive (nHCM) or obstructive HCM (oHCM).
- The primary efficacy endpoint will assess improvement in symptoms for the entire population (nHCM and oHCM). The final study population included a substantial majority of patients with nHCM, providing a robust opportunity to evaluate sotagliflozin in a patient group for whom effective treatment options remain limited, as well as a meaningful cohort of patients with oHCM.
- Lexicon continues to expect topline results in the first quarter of 2027.
Type 1 Diabetes (T1D) (ZYNQUISTA®)
- Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population for which there are no treatment options beyond insulin.
- STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) is approaching the patient exposure and safety data requirements previously identified by the U.S. Food and Drug Administration (FDA) as being adequate to support a resubmission of the company's New Drug Application (NDA), which Lexicon anticipates will occur in the fourth quarter of 2026 based on current estimated timing of data collection.
- The safety data received to date from this open-label trial continue to support the resubmission.
Viatris License for All Indications Ex-U.S. and Ex-Europe
- Lexicon continues to support licensee Viatris in its regulatory filing and commercial strategy for sotagliflozin outside of the U.S. and Europe.
- Viatris has obtained regulatory approval for heart failure in the United Arab Emirates and Bahrain and has submitted applications for regulatory approval for heart failure in several other markets, including Saudi Arabia, Canada, Australia, New Zealand, Mexico, Singapore, Oman, Thailand, Turkey, Malaysia, Philippines, and Kuwait. Viatris anticipates regulatory decisions in Australia and Canada and regulatory submissions in other markets in 2026.
LX9851
LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by licensee Novo Nordisk for obesity and associated metabolic disorders.
Obesity and Associated Cardiometabolic Disorders
- In March 2026, Novo Nordisk initiated a Phase 1 study investigating single and multiple ascending doses of LX9851 compared to placebo in overweight or obese people. The Phase 1 program is expected to be completed in the first quarter of 2027.
- Under the terms of Lexicon’s exclusive license agreement with Novo Nordisk, Lexicon received an upfront payment of
$45 million and two$10 million payments related to clinical development. Lexicon is eligible to receive a third$10 million milestone payment as early as later this year and up to an aggregate of$1 billion in upfront and development, regulatory and sales milestone payments. Lexicon is also eligible for tiered royalties on net sales of LX9851.
Pilavapadin (LX9211)
Discovered using Lexicon’s unique approach to gene science and target identification, pilavapadin is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and is exploring its potential in other indications.
Diabetic Peripheral Neuropathic Pain (DPNP)
- Pilavapadin has the potential to be the first oral, non-opioid drug therapy approved in neuropathic pain in more than 20 years.
- Lexicon continues to explore strategic opportunities to maximize the global potential of this investigative therapy.
Second Quarter 2026 Financial Highlights
Revenues: Total revenues were
Total revenues for the second quarter of 2025 were
Research and Development (R&D) Expenses: Research and development expenses for the second quarter of 2026 increased to
Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the second quarter of 2026 increased to
Net Loss: Net loss for the second quarter of 2026 was
Cash, Investments and Restricted Cash: As of June 30, 2026, Lexicon had
Hercules Capital Loan Facility
In May 2026, Lexicon entered into a
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 8:30 am ET / 7:30 am CT to review its financial and operating results and to provide a general business update. A live audio webcast of the call can be accessed by visiting the Events page of the Company’s investor relations website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on the website for 30 days.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
| Lexicon Pharmaceuticals, Inc. | |||||||||||||||
| Selected Financial Data | |||||||||||||||
| Consolidated Statements of Operations Data | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| (In thousands, except per share data) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||
| Revenues: | |||||||||||||||
| Net product revenue | $ | 680 | $ | 1,322 | $ | 1,770 | $ | 2,584 | |||||||
| Licensing and milestone revenue | — | 27,544 | 20,000 | 27,544 | |||||||||||
| Royalties and other revenue | 12 | — | 24 | — | |||||||||||
| Total revenues | 692 | 28,866 | 21,794 | 30,128 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of sales | 39 | 33 | 147 | 63 | |||||||||||
| Research and development, including stock-based | |||||||||||||||
| compensation of | 17,443 | 15,747 | 30,199 | 31,050 | |||||||||||
| Selling, general and administrative, including stock-based | |||||||||||||||
| compensation of | 9,750 | 9,350 | 18,984 | 20,958 | |||||||||||
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 | |||||||||||
| Income (loss) from operations | (26,540 | ) | 3,736 | (27,536 | ) | (21,943 | ) | ||||||||
| Interest and other expense | (2,609 | ) | (2,318 | ) | (4,199 | ) | (4,153 | ) | |||||||
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 | |||||||||||
| Loss on early extinguishment of debt | $ | (4,349 | ) | $ | — | $ | (4,349 | ) | $ | — | |||||
| Net income (loss) | $ | (31,775 | ) | $ | 3,252 | $ | (32,818 | ) | $ | (22,043 | ) | ||||
| Net income (loss) per common share, basic | $ | (0.07 | ) | $ | 0.01 | $ | (0.08 | ) | $ | (0.06 | ) | ||||
| Net income (loss) per common share, diluted | $ | (0.07 | ) | $ | 0.01 | $ | (0.08 | ) | $ | (0.06 | ) | ||||
| Weighted average common shares outstanding, basic | 437,653 | 363,294 | 419,050 | 362,687 | |||||||||||
| Weighted average common shares outstanding, diluted | 437,653 | 363,570 | 419,050 | 362,687 | |||||||||||
| As of | As of | ||||||||||||||
| Consolidated Balance Sheet Data | June 30, 2026 | December 31, 2025 | |||||||||||||
| (In thousands) | |||||||||||||||
| Cash and investments | $ | 190,610 | $ | 96,230 | |||||||||||
| Restricted cash | — | 29,000 | |||||||||||||
| Property and equipment, net | 1,651 | 1,863 | |||||||||||||
| Goodwill | 44,543 | 44,543 | |||||||||||||
| Total assets | 250,060 | 184,987 | |||||||||||||
| Current portion of long-term debt | — | 4,595 | |||||||||||||
| Long-term debt, net | 51,437 | 49,408 | |||||||||||||
| Accumulated deficit | (2,050,401 | ) | (2,017,583 | ) | |||||||||||
| Total stockholders' equity | 174,525 | 107,538 | |||||||||||||
